Evidence map›Paper›PMID 37808638›Full record

ArticlebioRxiv : the preprint server for biology2023

A comprehensive study of SARS-CoV-2 main protease (M

Francesco Costacurta, Andrea Dodaro, David Bante, Helge Schöppe, Bernhard Sprenger, Seyed Arad Moghadasi, Jakob Fleischmann, Matteo Pavan, Davide Bassani, Silvia Menin and 13 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Francesco CostacurtaInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Andrea DodaroMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.
David BanteInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Helge SchöppeInstitute of Pharmacy/Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Bernhard SprengerDepartment of Biochemistry, University of Innsbruck, Innsbruck, 6020, Austria.
Seyed Arad MoghadasiDepartment of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, United States.
Jakob FleischmannInstitute of Molecular Biology, University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Matteo PavanMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.
Davide BassaniMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.
Silvia MeninMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.
Stefanie RauchInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Laura KrismerInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Anna SauerweinInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Anne HeberleInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Toni RabensteinerInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Joses HoBioinformatics Institute, Agency for Science Technology and Research, Singapore.
Reuben S HarrisDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, United States.
Eduard StefanInstitute of Molecular Biology, University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Rainer SchneiderDepartment of Biochemistry, University of Innsbruck, Innsbruck, 6020, Austria.
Teresa KasererInstitute of Pharmacy/Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Stefano MoroMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F. Marzolo 5, 35131, Padova, Italy.
Dorothee von LaerInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.
Emmanuel HeilmannInstitute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Tyrol, Austria.

Funding

Project 5: Pandemic Virus Helicase InhibitorsU19AI171954 · NIAID · UNIVERSITY OF MINNESOTA · PI Reuben S Harris, Fang Li · 2022 to 2026
$100.9M
NIAID NIH HHS U19 AI171954
6 · The paper itself

Abstract

Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL

Indexed as

Antimicrobial resistanceensitrelvirnirmatrelvirnon-gain-of-function researchOmicronprotease inhibitor resistance mutationsSARS-CoV-2selection pressure experiments

Identifiers

PMID37808638
PMCPMC10557589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.